New Delhi, India -- (SBWire) -- 04/09/2018 --Critical Limb Ischemia (CLI) is a severe form of peripheral artery disease (PAD). It occurs with severe obstructions in the arteries which leads to reduced blood flow to the extremities. CLI causative occlusion could be acute or chronic. CLI may progress to severe pain and skin ulcers and is associated with high risk cardiovascular events such as myocardial infarction and mortality. CLI can also be divided into rest pain and tissue loss based on symptoms appears. Rest pain is a continuous burning pain of the lower leg whereas tissue loss is the development of gangrene or arterial insufficiency ulcers.

According to the latest report of DelveInsight, "Critical Limb Ischemia (CLI)- Market Insights, Epidemiology and Market Forecast- 2027", Around 300 per million cases of CLI arises each year in the United States. The estimated prevalence in Japan is 1 per million population whereas 4.2 per million Western European are suffering from this condition. CLI is associated with severe morbidity and mortality. On first year, 25% of patients will be dead, 30% may undergo amputation, and only 45% will remain alive with both limbs. At 5 years, more than 60% of patients with critical limb ischemia will be dead. More than 20% of adults age 70 and older are diagnosed with CLI. The prevalence of critical limb ischemia is slightly more in men than women

There is no drug approved for the treatment of Critical Limb Ischemia however, the current treatment practices are based on the symptoms and complexity of the conditions. Endovascular treatment and arterial surgery are other approaches to remove the blockage. Many players such as Pluristem Ltd., Rexgenero Ltd., Juventas Therapeutics, Inc., Caladrius Biosciences Inc., Reven Pharmaceuticals, Inc., and others are involved in developing therapies for Critical Limb Ischemia. The launch of potential emerging therapies such as PLX-PAD (Pluristem Ltd.), Rexmyelocel-T (Rexgenero Limited), JVS-100 (Juventas Therapeutics, Inc.) and CLBS12 (Caladrius Biosciences, Inc.) are expected to change the treatment landscape in upcoming years.

The latest report has covered detailed description about current treatment and medical practices. Complete Pipeline drugs profiling covering each and every phase of development with clinical trials data. Total market size of CLI is provided covering the 7MM with country-wise market analysis to better understand the areas of improvement and growth opportunities in the market. Complete Epidemiology and patient population details are provided covering the 7MM to better understand the distribution of the given indication in 7MM. Key emerging therapy details are also provided to better understand the future market competition and plan the strategies accordingly.

Reasons to buy:
-The report will help in developing business strategies by understanding trends shaping and driving the CLI market.
-To understand the future market competition in the CLI market and Insight reviews of the key market drivers and barriers.
-Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
-In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:
-Caladrius Biosciences,
-Juventas Therapeutics,
-Rexgenero Limited
-Pluristem Ltd.
And many others……………..

Request for sample pages: https://www.delveinsight.com/report-store/critical-limb-ischemia-market-insight-epidemiology-and-market-forecast

related sample pages: https://www.delveinsight.com/report-store/critical-limb-ischemia-pipeline-insight

Table of Contents:
1. Report Introduction
2. Critical Limb Ischemia Market Overview at a Glance
2.1. Global Market Size of Critical Limb Ischemia in 2017
2.2. Global Market Size of Critical Limb Ischemia in 2027
3. Disease Background and Overview: Critical Limb Ischemia
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. Critical Limb Ischemia Geography wise Prevalent Cases
4.2.1. 7MM Prevalent Cases of Critical Limb Ischemia (2017-2027)
4.2.2. Age Specific Prevalent Cases of Critical Limb Ischemia (2017-2027)
4.3. United States
4.3.1. Prevalent Cases of Critical Limb Ischemia in the US (2016-2027)
4.3.2. Age Specific Prevalent Cases of Critical Limb Ischemia in the US (2016-2027)
4.3.3. Diagnosed and Treatable population of Critical Limb Ischemia in the US (2016-2027)
4.4. EU-5
4.4.1. Assumptions and Rationale
4.4.2. Germany
4.4.2.1. Prevalent Cases of Critical Limb Ischemia in Germany (2016-2027)
4.4.2.2. Age Specific Prevalent Cases of Critical Limb Ischemia in Germany (2016-2027)
4.4.2.3. Diagnosed and Treatable population of Critical Limb Ischemia in Germany (2016-2027)
4.4.3. Italy
4.4.3.1. Prevalent Cases of Critical Limb Ischemia in Italy (2016-2027)
4.4.3.2. Age Specific Prevalent Cases of Critical Limb Ischemia in Italy (2016-2027)
4.4.3.3. Diagnosed and Treatable population of Critical Limb Ischemia in Italy (2016-2027)
4.4.4. Spain
4.4.4.1. Prevalent Cases of Critical Limb Ischemia in Spain (2016-2027)
4.4.4.2. Age Specific Prevalent Cases of Critical Limb Ischemia in Spain (2016-2027)
4.4.4.3. Diagnosed and Treatable population of Critical Limb Ischemia in Spain (2016-2027)
4.4.5. France
4.4.5.1. Prevalent Cases of Critical Limb Ischemia in France (2016-2027)
4.4.5.2. Age Specific Prevalent Cases of Critical Limb Ischemia in France (2016-2027)
4.4.5.3. Diagnosed and Treatable population of Critical Limb Ischemia in France (2016-2027)
4.4.6. United Kingdom
4.4.6.1. Prevalent Cases of Critical Limb Ischemia in the UK (2016-2027)
4.4.6.2. Age Specific Prevalent Cases of Critical Limb Ischemia in the UK (2016-2027)
4.4.6.3. Diagnosed and Treatable population of Critical Limb Ischemia in the UK (2016-2027)
4.5. Japan
4.5.1. Prevalent Cases of Critical Limb Ischemia in Japan (2016-2027)
4.5.2. Age Specific Prevalent Cases of Critical Limb Ischemia in Japan (2016-2027)
4.5.3. Diagnosed and Treatable population of Critical Limb Ischemia in Japan (2016-2027)
5. Current Treatment and Medical Practices
5.1. United States
5.2. Europe
5.3. Japan
6. Key Emerging Therapies
6.1. Key Cross Competition
6.2. PLX-PAD: Pluristem Ltd.
6.2.1. Regulatory Milestones
6.2.2. Clinical Development
6.2.3. Product Profile
6.2.4. Clinical Pipeline Activity
6.2.4.1. Ongoing Trials Information
6.2.4.2. Clinical Trial by Phase
6.3. Rexmyelocel-T: Rexgenero Limited
6.3.1. Regulatory Milestones
6.3.2. Clinical Development
6.3.3. Product Profile
6.3.4. Clinical Pipeline Activity
6.3.4.1. Ongoing Trials Information
6.3.4.2. Clinical Trial by Phase
6.4. JVS-100: Juventas Therapeutics, Inc.
6.4.1. Regulatory Milestones
6.4.2. Clinical Development
6.4.3. Product Profile
6.4.4. Clinical Pipeline Activity
6.4.4.1. Ongoing Trials Information
6.4.4.2. Clinical Trial by Phase
6.5. CLBS12: Caladrius Biosciences, Inc.
6.5.1. Regulatory Milestones
6.5.2. Clinical Development
6.5.3. Product Profile
6.5.4. Clinical Pipeline Activity
6.5.4.1. Ongoing Trials Information
6.5.4.2. Clinical Trial by Phase
To be continued in report…
7. Critical Limb Ischemia Market Size
7.1. Key Findings
7.2. Total 7MM Critical Limb Ischemia Market Analysis
7.2.1. Overview of Total Critical Limb Ischemia Market (2016-2027)
8. 7MM Critical Limb Ischemia: Country-Wise Market Analysis
8.1. United States Market Size
8.1.1. Market Analysis
8.1.2. Emerging therapies analysis: Impact on the market
8.2. Germany Market Size
8.2.1. Market Analysis
8.2.2. Emerging therapies analysis: Impact on the market
8.3. France Market Size
8.3.1. Market Analysis
8.3.2. Emerging therapies analysis: Impact on the market
8.4. United Kingdom Market Size
8.4.1. Market Analysis
8.4.2. Emerging therapies analysis: Impact on the market
8.5. Spain Market Size
8.5.1. Market Analysis
8.5.2. Emerging therapies analysis: Impact on the market
8.6. Italy Market Size
8.6.1. Market Analysis
8.6.2. Emerging therapies analysis: Impact on the market
8.7. Japan Market Size
8.7.1. Market Analysis
8.7.2. Emerging therapies analysis: Impact on the market
9. Report Methodology
9.1. Sources Used
10. Delveinsight Capabilities
11. Disclaimer

About Delveinsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses.

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.